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Abstract
The optimal dialysis dose for acute kidney injury is a matter of great
controversy. Clinical trials, predominantly single-center studies, have
shown conflicting results. The Acute Renal Failure Trial Network
(ATN) Study was designed to compare clinical outcomes between
patients allocated to an intensive dose versus a less-intensive dose
of renal replacement therapy. Recently, the results of this large
randomized controlled multicenter study were published.  The
present article will discuss certain aspects of this trial: the overall
design, the baseline patient characteristics, and comparison of the
results with earlier studies. Finally, the article will address the
implications of the ATN Study results for clinical practice.
Introduction
Since the original formulation of the dose concept for renal
replacement therapy more than 30 years ago [1] and the
establishment of a link between dose and clinical outcome
[2,3], individualized patient dosing based on urea clearance
is now routine in end-stage renal disease (ESRD) patients.
More recently, similar principles have been applied to
critically ill patients with acute kidney injury (AKI) treated both
with continuous renal replacement therapy (CRRT) and with
intermittent modalities.
Using the normalized effluent rate as a dose surrogate in
postdilution continuous venovenous hemofiltration, Ronco
and colleagues reported higher survival in patients receiving a
dose of 35 or 45 ml/hour/kg than in patients receiving a dose
of 20 ml/hour/kg [4]. A second randomized controlled trial
(RCT) demonstrated higher survival and renal recovery rate in
AKI patients receiving an average of six intermittent hemo-
dialysis (IHD) treatments per week compared with patients
treated an average three times per week [5]. Since these two
initial studies, three additional dose/outcome RCTs in CRRT
[6-8] and one RCT in intermittent therapy [9] have been
published, producing mixed results.
When the Acute Renal Failure Trial Network (ATN) Study was
designed, only two of the CRRT dose/outcome studies [4,6]
and one of the intermittent therapy studies [5] had been
published. The preponderance of evidence at that time sug-
gested a clinical benefit for more aggressive dialysis dosing in
AKI. A major limitation of the Ronco and colleagues [4] and
Schiffl and colleagues [5] studies, however, along with the
subsequent dose/outcome studies, was their predominant
single-center design. Accordingly, the ATN investigators
reasoned that a multicenter trial was required to clarify the effect
of dialysis dose on AKI patient outcome. The investigators
therefore embarked on a multicenter trial involving academic
and Veterans Affairs hospitals in the United States, conducted
over the time period of 2003 to 2007. The study was published
by the New England Journal of Medicine, in electronic form on
20 May 2008 and in print form on 3 July 2008 [10].
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The ATN Study failed to show a beneficial effect for higher
dose of renal replacement therapy on the survival of AKI
patients. This is an important finding and the investigators
should be congratulated for their efforts. Nevertheless,
because of the landmark nature of the trial, a critical analysis
is certainly in order.
The purpose of the present editorial is several-fold. First, we
shall discuss the overall design of the ATN Study, with
emphasis on the fact that this trial evaluated the intensity of
renal support and was not a comparison of different dialysis
modalities. Second, we shall address the baseline patient
characteristics, especially with regard to illness severity and the
manner in which this influenced dialysis modality allocation.
Third, we shall highlight the major results, including a compari-
son with the results of prior studies, and provide potential
explanations for the different results. Finally, we discuss the
implications of the ATN results for clinical practice.
Design of the Acute Renal Failure Trial
Network Study
As opposed to previous dose/outcome RCTs, which were
either single-center trials or dual-center trials, the ATN Study
involved 27 American sites at which 1,124 patients were
randomized to a relatively high dialysis dose (intensive dose
group) or to a conventional dialysis dose (less-intensive dose
group). Once this randomization based on dose occurred, the
actual dialysis treatment modality was determined by illness
severity, as estimated by the cardiovascular component of the
Sepsis-related Organ Failure Assessment (cSOFA) [11]. IHD
was prescribed for patients with relative hemodynamic
stability at baseline (cSOFA score = 0, 1, or 2), while hemo-
dynamically unstable patients (cSOFA score = 3 or 4) were
treated with either CRRT or sustained low efficiency dialysis
(SLED). The initial modality assignment was not fixed, how-
ever, as patients could transition between IHD and CRRT/
SLED depending on their cSOFA score, although these
transitions occurred strictly within the assigned dose group.
An intensive dose was defined as 35 ml/kg/hour (prescribed)
in CRRT and as a delivered urea Kt/V value of 1.2 in each of
six treatments per week in IHD and SLED. A less-intensive
dose was defined as 20 mg/kg/hour (prescribed) in CRRT
and as a delivered urea Kt/V value of 1.2 in each of three
treatments per week for IHD and SLED. The primary endpoint
for the study was all-cause mortality at 60 days, while
recovery of renal function was an important secondary
endpoint.
A detailed discussion of the urea Kt/V parameter is beyond
the scope of the present paper, but this is the clinical
standard for estimating chronic hemodialysis dose in ESRD
patients [12]. The Kt/V parameter is essentially a dimension-
less urea clearance that is normalized to patient body size (or,
more specifically, to the urea distribution volume). An
important point to note is that, although the relationship
between the Kt/V value and patient survival has been
explored exhaustively in ESRD, no such assessment in AKI
patients had been performed prior to the ATN Study.
Moreover, no clinical validation of any methodology for
estimating the Kt/V parameter in AKI patients has ever been
performed, and the approach used for this in the ATN Study
was one developed for ESRD patients.
Failure to account for the qualitative and quantitative dose
differences between IHD and CRRT precludes an appro-
priate interpretation of the ATN outcome data. Comparison
between the CRRT and IHD doses is complex due to the
nonsteady-state nature of the latter therapy. A physiologically
logical approach to comparing the two modalities is the
standardized urea Kt/V  parameter, as described by Gotch
[13]. This parameter provides a continuous equivalent
estimate of weekly urea removal for disparate therapies. In the
ATN Study, the weekly standardized urea Kt/V value for
intensive IHD can be estimated to be approximately 4.0 and
that for less-intensive CRRT to be approximately 5.0. On a
time-averaged basis, therefore, greater urea removal occurred
in patients receiving less-intensive CRRT on a given day than
in those receiving intensive IHD. This uncertain separation of
the dose during periods of unknown duration makes failure to
observe a treatment effect unsurprising in the study.
As indicated clearly above (and contrary to some miscon-
ceptions about the study), the ATN Study was not a
comparison of different dialysis modalities. Instead, the ATN
Study design was consistent with American clinical practice,
in that a continuum of care approach for AKI (that is,
matching the appropriate therapy to the patient’s clinical
status at different time points) was utilized. In this regard, the
design implies IHD was not considered an appropriate
modality for hemodynamically unstable patients by the
investigators, the design of prior trials notwithstanding [14].
Of note, the relatively high rate of severe hypotensive events
in patients treated with IHD (see below), despite being
judged clinically ‘hemodynamically stable’, both supports the
ATN approach to modality assignment and suggests that, from
a hemodynamic point of view, a greater number of patients may
have benefited from more liberal use of CRRT than that chosen
for the study. On the other hand, the intent-to-treat trial design
complicates analysis, as discussed subsequently.
Finally, an important inclusion criterion that merits mention
relates to pre-existing chronic kidney disease. Male patients
with a baseline serum creatinine >2.0 mg/dl and female
patients with a baseline serum creatinine >1.5 mg/dl were
excluded from the trial. The relatively low mean premorbid
serum creatinine (1.1 mg/dl in both groups) reflects this
exclusion of patients with moderate to severe chronic kidney
disease. This exclusion is an important consideration due to
the high risk of progression to ESRD after an episode of AKI
in the patient group with moderate to severe chronic kidney
disease, especially in light of the relatively high rate ofPage 3 of 7
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nonrenal recovery even after exclusion of these high-risk
patients (see below).
Patient baseline characteristics and dialysis
modality allocation in the Acute Renal Failure
Trial Network Study
The intensive and less-intensive dose groups were very well
matched overall with regard to demographic and clinical
characteristics at the time of study enrollment. A point of
emphasis, however, is that the baseline characteristics along
with the patient outcomes within each dose group are really
composite (blended) data provided by relatively stable
patients (treated initially with IHD) and by very critically ill
patients (treated initially with CRRT or SLED). Some notable
features of the enrolled populations include the following.
The leading causes of AKI – as is usual – were ischemia,
sepsis and multifactorial causes, with nephrotoxins being
much less common.
Secondly, because the mean body weight before acute
illness was 84 kg, a reasonable assumption is that the actual
body weight used for dosing (at least at the beginning of
dialysis therapy) was minimally 90 kg – a figure consistent
with several recent reports from the critically ill AKI patient
population. Although specific data are not provided in the
paper, a reasonable assumption is that weight gain might
have been substantially greater in the patients initially treated
with CRRT versus those treated with IHD due to their greater
illness severity and more severe organ failure.
Thirdly, the average length of stay both in the hospital
(approximately 10 to 11 days) and in the intensive care unit (6
to 7 days) prior to renal replacement therapy initiation was
extremely long. Although the average duration of stay in the
intensive care unit prior to CRRT initiation was even longer
(8 days) in the recent CRRT dose/outcome study performed
by Tolwani and colleagues [8], this duration has been much
shorter in other studies. For instance, in a recent RCT
comparing CRRT and IHD, the stay duration was only 2 to
3 days [14]. The timeliness of initiation of renal support in the
ATN Study therefore needs to be considered when
interpreting its findings. It should be noted that the protocol’s
allowance for one IHD treatment or up to 24 hours of CRRT
prior to enrollment may have contributed to this relatively late
start. Indeed, 65% of enrolled patients had received one renal
replacement therapy session before study inclusion at a time
when illness severity undoubtedly was at its peak in a
substantial percentage. Moreover, this is a potentially impor-
tant dose confounder, as there was no knowledge of the
dose provided to these patients on the first day, when it
probably mattered most.
Fourthly, the mean Acute Pathophysiology and Chronic
Health Evaluation (APACHE) II score of approximately 26
suggests the CRRT/SLED patient group was quite critically
ill. Based on the reported standard deviation and this mean
value, the average APACHE II score in the CRRT/SLED
subgroup was probably at least 28. By comparison, the mean
APACHE II scores were approximately 23, 25, and 26,
respectively, in the studies of Ronco and colleagues [4],
Saudan and colleagues [7], and Tolwani and colleagues [8].
A relatively high plasma creatinine, the result of both a
predominantly male patient population and late renal
replacement therapy initiation, may have contributed to the
higher APACHE II score.
Finally, additional evidence supporting the overall high level of
illness severity in the study is the high percentage (78%) of
patients who were oliguric.
In accordance with the baseline cSOFA score, CRRT or
SLED was the initial modality in 55% of patients and IHD was
the initial modality in 45% of patients. Among the most
critically ill patients with hemodynamic instability at baseline
(cSOFA score = 3 or 4), however, CRRT was the clearly
dominant modality. Specifically, in this group, CRRT repre-
sented >95% of treatments while SLED was utilized in <5%
of treatments. This low utilization of SLED in hemodynamically
unstable patients occurred despite the investigators’ ability to
prescribe either SLED or CRRT in the study. These findings
corroborate large observational trials [15-17] that demon-
strate CRRT is the standard of care for hemodynamically
unstable patients with AKI. Moreover, these results suggest
clinicians do not yet believe SLED is clinically equivalent to
CRRT for the most critically ill patients, and the results also
suggest that the probable use of SLED in this patient
population has been overestimated, based on information
appearing in the literature and provided at congresses.
Characteristics of renal replacement
therapies in the Acute Renal Failure Trial
Network Study
A total of 11,602 renal replacement treatments were
provided in the study. As noted above, the number of treat-
ments provided by SLED was very small (approximately 2.5%
of all treatments). This section therefore includes the treat-
ment characteristics for IHD and CRRT only.
Intermittent hemodialysis
A delivered Kt/V value of 1.2 was targeted, so the prescribed
Kt/V level was in the 1.3 to 1.4 range per treatment to
account for shortfalls in the delivery of the prescribed IHD
dose. Of note, the mean delivered Kt/V value of 1.3 per
treatment (after the first treatment) was actually higher than
the targeted value. This feat is almost never accomplished in
the real world, and previous studies have indicated that the
delivered dose may fall short of the prescribed dose by 30%
or more when provided in the intensive care unit for AKI
[18,19]. This level of dose delivery required a mean treatment
duration of 4 hours, a mean blood flow of 360 ml/minute and
a mean dialysate flow of 720 ml/minute, all of which clearly
Available online http://ccforum.com/content/12/5/308represent a best-case scenario for IHD in this setting. Overall,
it may be very difficult to apply these results in actual clinical
practice, especially on a repeated basis.
The surprisingly low net ultrafiltration volumes achieved in the
IHD patients are worth mentioning. The paper reported the
average number of IHD treatments per week and the average
net ultrafiltration volume per treatment. Based on the
assumption that the cumulative net ultrafiltration volume over
the period of 1 week is the product of these parameters, the
weekly  ultrafiltration volume was only 9.4 l (1.7 l/treatment x
5.4 treatments/week) and 6.3 l (2.1 l/treatment x 3.0 treatments/
week) in the intensive and less-intensive dose groups,
respectively. Although the residual urine output could have
supplemented the net fluid output in some patients, these
ultrafiltration volumes are much lower than those achieved
routinely in critically ill patients treated with CRRT – whose
net volume removal requirements are usually at least 2.5 to
3 l/day, or approximately 20 l/week. (In fact, among patients
treated with CRRT, the mean daily net ultrafiltration volume
per day was approximately 2.7 l in both dose arms of the ATN
Study.)
The relatively low illness severity of the IHD group may mean
that these patients simply had lower volume removal
requirements than the more critically ill patients treated with
CRRT, or that large net ultrafiltrate volumes had already been
achieved in those patients initially treated with CRRT and
then transitioned to IHD. The potentially inadequate nature of
the less-intensive IHD regimen with respect to fluid removal,
however, is highlighted by the relatively high ratio (1:9) of off-
schedule isolated ultrafiltration treatments to actual IHD treat-
ments. In addition, a contributing factor may have been the
inability to achieve the prescribed volume removal due to
hypotension, as discussed below.
Previous studies have not consistently confirmed the
theoretical CRRT advantage of better preservation of hemo-
dynamic stability relative to IHD, and a recent RCT suggested
that IHD and CRRT can be used interchangeably in critically
ill AKI patients [14]. The ATN hemodynamic data strongly
challenge this notion, however, and suggest the incidence of
hypotension in IHD has been generally underestimated in the
past, despite advances in hemodialysis technology. Severe
hypotension – defined as an episode necessitating discon-
tinuation of treatment – occurred in 1.5% to 2% (average,
1.7%) of all IHD treatments, and this frequency was not
dependent on the treatment dose. By comparison of Supple-
mentary Tables 5 and 6 from the New England Journal of
Medicine publication [10], only 0.7% of CRRT treatments
were terminated due to hypotension. The frequency at which
severe hypotension occurred in the IHD-treated patients was
therefore 2.5-fold greater than the same frequency in patients
treated with CRRT – even though the latter group was more
critically ill, more hemodynamically unstable, and required
much higher net ultrafiltration volumes for fluid balance.
These hemodynamic data are particularly important in light of
the continuing belief by many experts that any episode of
hypotension in an AKI patient, even if very transient, can
cause further kidney injury and possibly reduce the likelihood
of renal recovery.
Continuous renal replacement therapy
More than 95% of all treatments provided to hemody-
namically unstable patients consisted of continuous therapy
in the study. It is important to note that, because the CRRT
doses of 35 ml/kg/hour and 20 ml/kg/hour were delivered
with predilution continuous venovenous hemodiafiltration
(CVVHDF), the effective delivered dose was less when the
effect of dilution on actual solute clearance is considered
[20,21] (see below). The average daily duration of therapy
was approximately 21 hours in both groups, allowing for a
high percentage of the prescribed dose to be delivered.
Similar to the IHD dose delivery data, the relevance of these
best-case results to standard clinical practice are unclear.
The average reported effluent volumes per day in the intensive
and less-intensive dose groups were approximately 50 l and
30 l, respectively, with an approximately equal contribution from
dialysate (diffusion) and replacement (convection). These
figures, however, are difficult to reconcile with the additional
data provided. For the intensive dose group, the average hourly
effluent rate, which is determined by summing the mean values
of the individual components (dialysate rate, replacement rate,
and net ultrafiltration rate), was 2,930 ml/hour. When this value
is multiplied by the mean daily duration of treatment for this
group (20.9 hours), a mean daily effluent volume of 61.5 l is
determined. The reported mean daily effluent volume (50 l) is
therefore approximately 20% less than the same parameter
estimated in the above manner (61.5 l). When the same
calculations are performed for the less-intensive group, the
reported mean daily effluent volume (30 l) is also approximately
20% less than the calculated value (37.4 l).
Additional evidence raising questions about which CRRT
dose was actually provided in the study can be derived from
body-weight estimations. As suggested previously, one of the
problems with the study is that the actual body weights used
for CRRT dosing were not reported. Nevertheless, this average
dosing weight can be estimated by dividing the reported
mean hourly effluent rate (2,930 ml in the intensive dose
group) by the mean delivered dose for this group
(35.8 ml/hour/kg). When this approach is followed, the
calculated value for the mean body weight is 81.8 kg. A
similar calculation performed for the less-intensive dose
group yields a mean body weight of 80.9 kg. These calcu-
lated dosing body weights, however, are implausibly less than
the reported mean premorbid weight (weight before acute
illness) of 84.1 kg. Based on an assumed 8% to 10% body-
weight increase in fluid volume from this premorbid weight,
the actual body weight used for dosing CRRT may well have
been 91 to 92 kg, at least at therapy initiation.
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which CRRT dose was actually delivered, the issue of effec-
tive dose reduction due to predilution must be addressed
[20,21]. The combination of blood flow rates and replace-
ment fluid flow rates used in the study suggest an effective
dose reduction of approximately 15% in the intensive dose
group and of approximately 9% in the less-intensive group.
Furthermore, although the dose delivery was relatively high,
still only 89% and 95% of the prescribed dose were
delivered to the intensive and less-intensive dose groups,
respectively. Therefore, even without consideration of above
questions relating to the accuracy of the mean doses of 35.3
and 22 ml/kg/hour reported in the article for the intensive and
less-intensive dose groups, respectively, the effective doses
were at best only 27 and 19 ml/kg/hour, respectively.
Finally, it should be emphasized that use of the term dose in
the study is limited to the clearance of a small solute (urea) in
a specific CRRT modality (predilution CVVHDF). In this
regard, it is instructive to compare the manner in which CRRT
was delivered in the ATN Study with the manner in which it
was delivered in the two single-center RCTs that reported a
positive correlation between dose and survival. In one of
these latter trials, since the CRRT modality used was post-
dilution continuous venovenous hemofiltration, effective dose
decreases due to dilution effects were not relevant [4].
Furthermore, the percentage delivery of the prescribed dose
was higher because increases in flow rates were prescribed
to compensate for therapy down-time. Lastly, as a purely
convective therapy, continuous venovenous hemofiltration
provides a much broader solute removal spectrum from a
molecular weight perspective than CVVHDF at similar
effluent rates, and many AKI experts believe this contributed
to the survival benefit observed with higher effluent rates in
the study of Ronco and colleagues. In the second positive
CRRT dose/outcome study [7], even though the modality
associated with better survival was also the predilution
CVVHDF, the dose was higher (42 ml/kg/hour) and a greater
proportion of the dose was provided by convection rather
than by diffusion, relative to the ATN Study.
Major findings of the Acute Renal Failure
Trial Network Study
As mentioned previously, all-cause mortality was not different
between the intensive dose group (53.6%) and the less-
intensive dose group (51.5%) at 60 days (Figure 1). It is critically
important, however, to understand that the two curves shown in
the figure are composite in nature because they incorporate
data from patients initially treated with IHD (low cSOFA score)
and those initially treated with CRRT or SLED (high cSOFA
score). In this regard, it is interesting to note that intensive IHD
(in relatively well patients) was associated with a 33% increase
in death risk relative to less-intensive IHD. Conversely, intensive
CRRT/SLED was associated with a 7% decrease in death risk
relative to less-intensive therapy. Furthermore, in the oliguric and
septic subgroups, the dose likewise did not have a significant
effect on mortality. Finally, none of the secondary endpoints –
including inhospital mortality, renal recovery, and outcomes
related to intensive care unit and hospital lengths of stay – was
impacted significantly by treatment dose.
With regard to renal recovery, the percentage of patients who
were considered to have no renal recovery was approximately
75% in both dose groups. Although this seems to be an
Available online http://ccforum.com/content/12/5/308
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Figure 1
Effect of renal replacement dose on survival of acute kidney injury patients. Acute Renal Failure Trial Network Study. Reprinted with permission from [10].inordinately high percentage on first inspection, two qualifi-
cations are in order. First, this figure is based on all patients
enrolled in the trial while previous observational studies have
limited assessment of this outcome to patients surviving to
hospital discharge. Second, this outcome was measured at
28 days while the previous observational studies focused on
this outcome have primarily used hospital discharge as the
assessment time point.
The particular methodology used in the ATN Study artificially
increased the rate of nonrenal recovery, relative to the afore-
mentioned observational studies. On the other hand, even
after accounting for the above differences, the rate of renal
recovery at hospital discharge was estimated to be sub-
stantially lower (approximately 50%) in the ATN Study than
what has been reported previously (60% to 90%) [16,17].
Furthermore, the exclusion of patients with moderate to
severe chronic kidney disease, who are at particular risk for
progression to ESRD after AKI, most probably mitigated this
result, at least to a certain extent. The clinical and health
economic implications of renal nonrecovery after AKI are
being increasingly recognized [22,23].
Although the dose did not have a significant impact on renal
recovery, it is not clear from the reported data whether the
dialysis modality played a role. This is a relevant question
because recent large observational trials suggest that the use
of CRRT results in a higher rate of renal recovery after AKI
than the use of IHD [16,17]. Moreover, this issue of renal
recovery raises a larger question about overall trial design. In
an intent-to-treat design, patient outcomes are attributed to
the initial treatment assignment – and in most studies
employing this design, the initial treatment assignment is the
only one that is relevant. In the ATN trial design, however,
treatment transfers (CRRT/SLED to IHD or vice versa) occur-
red in a significant percentage of patients.
With regard to renal recovery, a specific scenario that causes
concern is a patient initially treated with CRRT over a period
of several days with progressively improving hemodynamic
stability. Subsequently, this patient is treated with IHD, during
which time several episodes of hypotension occur. If this
particular patient fails to recover renal function, a probable
cause would be the hypotension occurring during IHD.
Owing to the intent-to-treat design, however, the nonrecovery
of renal function would be attributed to CRRT. In light of the
high rate of nonrecovery of renal function and the high
incidence of hypotension in patients treated with IHD in the
ATN Study, this is a highly relevant scenario and one that
needs to be clarified further in future analyses by the ATN
investigators.
Clinical implications of the Acute Renal
Failure Trial Network Study
Based on the ATN Study’s design, which does not easily
permit the assessment of the separate effects of IHD and
CRRT on patient outcome, it is not clear what impact the trial
will have on clinical practice. Furthermore, at least with
respect to CRRT, the effective treatment doses actually
applied, especially to the intensive group, are unclear but are
significantly different from previous studies showing a
positive correlation between dose and survival.
From a more general perspective, as articulated recently [24],
the manner in which data were interpreted from a previous
American dose/outcome study performed in the late 1970s
should serve as an argument against a rush to judgment. The
National Cooperative Dialysis Study was the first study
assessing the effect of the chronic hemodialysis dose on the
outcome of ESRD patients [2]. Unfortunately, the results from
this study were misinterpreted by the study investigators, who
made ill-advised recommendations to the clinical community
[25]. These recommendations most probably contributed to a
systematic decrease in hemodialysis dose prescriptions in
the United States and to an increased mortality over a
prolonged period of time [26].
In general, as is the case with the dose of a drug, there is a
dose/response effect for dialysis as it relates to an effect on
survival. Even with the ATN data now available, however, the
inflection point of the dose/survival curve at which further
increases in treatment dose have no beneficial effect on
survival has not been determined conclusively (Figure 2).
Since this inflection point has not yet been established, we
think it is wise to suggest caution in clinical practice [24]. We
should encourage physicians not to make any significant
changes to their current practice, and especially not to take
decisions that may put patients at risk of underdialysis. We
should not forget what we learnt from the experience with
chronic dialysis, where dialysis dose was frankly over-
Critical Care    Vol 12 No 5 Ronco et al.
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Figure 2
Renal replacement dose/response relationship in acute kidney injury.
Proposed by Ronco. Reprinted with permission from [24].estimated in the years following the National Cooperative
Dialysis Study [25]: these years led to increased morbidity
and mortality due to unscheduled underdialysis [26].
Conclusion
The ATN Study was a prodigious undertaking for which the
investigators deserve enormous credit. Although the results
clearly add to our understanding of the effect of dialysis dose
on outcome in AKI, a number of questions remain. These
questions, many of which are addressed in the present
editorial, preclude the development of specific recommen-
dations in this area. Our recommendation, therefore, is that
clinicians pursue a conservative approach that does not
involve substantial changes in clinical practice. This is
especially true for CRRT dosing in light of the ongoing
dose/outcome RENAL trial in Australia and New Zealand, the
results of which will probably consolidate the evidence and
clarify the dose/outcome relationship.
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